OVERVIEW
The Global Spine Biologics Market is expected to hit USD 2.92 billion by 2025, rising by 3.91% to CAGR during the forecast period. Factors such as increasing incidence of spinal disorders, growing healthcare expenditure in developing countries due to rising income levels, growing cases of obesity, awareness of newly developed techniques and devices for spine treatment, technical developments and rising demand for minimally invasive spine surgery are driving demand for the Global Spine Biologics market.
TABLE OF CONTENT
1 Global Spine Biologics Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope
2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data from Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data from Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
3 Global Spine Biologics Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography
4 Global Spine Biologics Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis
5 Global Spine Biologics Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies
6 Global Spine Biologics Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7 Global Spine Biologics Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)
8 Global Spine Biologics Market – By Product Type (Market Size – & million/billion)
8.1 Platelet Rich Plasma (PRP)
8.2 Bone Graft Substitutes
8.3 Bone Marrow Aspirate Concentrate (BMAC) Therapy
8.4 Bone Grafts
9 Global Spine Biologics Market – By Surgery Type
9.1 Transforaminal Lumbar Interbody Fusion (TLIF)
9.2 Anterior Cervical Discectomy and Fusion (ACDF)
9.3 Lateral Lumbar Interbody Fusion (LLIF)
9.4 Anterior Lumbar Interbody Fusion (ALIF)
9.5 Others
10 Global Spine Biologics Market – By Geography (Market Size – & million/billion)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 U.K
10.3.2 Germany
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia-Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 South Korea
10.4.5 Rest of APAC
10.5 Rest of the World
10.5.1 South America
10.5.2 Middle East
10.5.3 Africa
11 Global Spine Biologics Market – Entropy
11.1 New product launches
11.2 M&A’s, collaborations, JVs and partnerships
12 Global Spine Biologics Market -Company Profile (Key Players)
12.1 Market Share, Company Revenue, Products, M&A, Developments
12.2 Medtronic PLC
12.3 Depuy Synthes
12.4 DR PRP USA LLC
12.5 Stryker Corporation
12.6 Exactech, Inc.
12.7 Orthofix International N.V.
12.8 K2M, Inc.
12.9 Nuvasive, Inc.
12.10 Wright Medical Technology, Inc.
12.11 Nutech
12.12 Company 11 & more
13 Global Spine Biologics Market – Appendix
13.1 Sources
13.2 Abbreviations1
